Goldman Sachs has removed MAKO Surgical MAKO from the Americas Conviction Buy List but maintains its Buy rating and has raised the price target from $37 to $44.
Market News and Data brought to you by Benzinga APIs© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
